Pharma Mar

Spain Updated 9 July 2026

Pharma Mar is an API manufacturer based in Spain. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with EMA, FAMHP (BE) and MPA (SE). Its GMP standing is certified by EMA and AEMPS (ES). Its most recent recorded inspection, by US FDA, closed on 26 January 2023 as VAI.

active US DMFs

valid CEPs

registered plants 1 with an FDA FEI number

filings across 9 regulators

These figures were checked against the regulators' own files on 25 July 2026

Plants

1 of 1 confirmed

Inspections

4 of 4 confirmed

EU GMP

1 of 1 confirmed

Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

26 January 2023 VAI US FDA
21 February 2019 VAI US FDA
24 April 2015 VAI US FDA
30 July 2009 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site	FDA FEI
madrid, United Arab Emirates	Not on file
Madrid, Spain	Not on file
Spain, Spain	3004983316
Colmenar Viejo, Spain	Not on file

What they file, and where

Molecule	Regulators	Docs
Lurbinectedin	SFDA (Saudi Arabia), US FDA	2
Trabectedin	SFDA (Saudi Arabia), US FDA	2

Also appears on these molecule pages

Lurbinectedin API Trabectedin API

Filings and GMP by regulator

Regulator	Filings	GMP certificates
EMA	6	1
FAMHP (BE)	4	None
MPA (SE)	4	None
INFARMED (PT)	4	None
AEMPS (ES)	4	1
AIFA (IT)	4	None

Comparing suppliers?

Choose your molecules and target markets. Pharma Mar comes back tiered against every other supplier able to file there.

Start for free

No sales call.

Open risk flags

The most recent inspection outcome was VAI, on 26 January 2023.

Sources on this page

FDA: Drug master files, establishment registration, inspection classifications
EDQM: Certificates of suitability
EudraGMDP and national regulators: GMP certificates